Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -12.22M | -11.02M | -10.12M | -10.97M | -12.03M |
| Total Depreciation and Amortization | 603.80K | 580.40K | 574.70K | 538.50K | 510.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.38M | -881.40K | -438.20K | -419.10K | -390.80K |
| Change in Net Operating Assets | 577.30K | 349.60K | 86.30K | -243.00K | -549.70K |
| Cash from Operations | -12.42M | -10.97M | -9.89M | -11.10M | -12.46M |
| Capital Expenditure | -26.40K | -54.40K | -85.00K | -125.70K | -168.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 734.80K | 9.77M | 19.54M | 12.70M | 5.72M |
| Cash from Investing | 708.50K | 9.72M | 19.46M | 12.58M | 5.55M |
| Total Debt Issued | -- | -- | -- | 396.50K | 793.00K |
| Total Debt Repaid | -601.00K | -496.00K | -391.00K | -260.50K | -130.00K |
| Issuance of Common Stock | 13.45M | 13.44M | 13.44M | 6.73M | 21.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.14M | 15.27M | 15.39M | 7.98M | 928.70K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.43M | 14.02M | 24.95M | 9.46M | -5.98M |